CCM
PLSE icon

Cadence Capital Management’s Pulse Biosciences PLSE Stock Holding History

Cadence Capital Management’s Portfolio PLSE Stock Details PLSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-11,832
Closed -$409K – 709
2017
Q2 		$409K Sell
11,832
-18,398
-61% -$506K 0.03% 550
2017
Q1 		$617K Buy
+30,230
New +$412K 0.04% 470

Other funds holding PLSE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HCS
Harvest Capital Strategies San Francisco, California $73.7M AUM 7.47% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
TF
TIAA FSB Jacksonville, Florida $27.6B AUM 14.26% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Cadence Capital Management's PLSE Position: Q3 2017 in Review

Cadence Capital Management sold out of Pulse Biosciences (PLSE) in Q3 2017, closing a stake of 11,832 shares — an estimated $409K sold.

Cadence Capital Management first reported a position in PLSE in Q1 2017 and held it in 2 quarters. The position peaked at $617K in Q1 2017. 43 funds tracked by Wall St. Rank hold PLSE as of Q3 2017.

  • Cadence Capital Management reported no remaining Pulse Biosciences position as of Q3 2017 after selling out during the quarter.
  • Cadence Capital Management sold 11,832 Pulse Biosciences shares in Q3 2017, an estimated $409K.
  • Cadence Capital Management first reported a position in Pulse Biosciences in Q1 2017 and held it in 2 quarters.
  • Cadence Capital Management's Pulse Biosciences position peaked at $617K in Q1 2017.
  • 43 funds tracked by Wall St. Rank held Pulse Biosciences as of Q3 2017.

Based on Cadence Capital Management's 13F filing for Q3 2017, filed 9 Nov 2017.